New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
08:47 EDTMSFT, ORCL, UBS, TEVA, BBRY, DISH, PFE, HPQ, F, BRCM, DRI, GE, INTC, LVSOn the Fly: Periodicals Wrap
WSJ: Las Vegas Sands' (LVS) Adelson: 'I'd spend $10B in Japan'... Starboard wants Red Lobster spinoff vote by Darden (DRI) shareholders...HP's (HPQ) Whitman: 'Hardware increasingly being pivoted to software'...Chip makers (INTC, BRCM) race to offer faster mobile networks...Pfizer (PFE) to again ship thyroid drug Levoxyl following recall...REUTERS: GE (GE) to increase energy research $10B by 2020...BLOOMBERG: Ford (F) to dump Microsoft (MSFT) for BlackBerry (BBRY) in next-generation Sync...UBS (UBS) wants immunity from U.S., EU in fx investigations...LightSquared says Dish's (DISH) Ergen can agree to plan or risk $1B...Teva (TEVA) advances amidst takeover speculation...OTHER NEWS: Oracle (ORCL) close to buying BlueKai for about $400M, Business Insider reports.
News For LVS;DRI;HPQ;INTC;BRCM;PFE;GE;F;MSFT;BBRY;UBS;DISH;TEVA;ORCL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | all recent news | >>
June 17, 2015
07:25 EDTPFEPiper calls Bristol 'modestly overvalued,' starts shares with sell
Subscribe for More Information
07:12 EDTTEVANeurocrine price target raised to $87 from $63 at Piper Jaffray
Subscribe for More Information
06:36 EDTGEGeneral Electric, Altran Technologies announce intention to form alliance
Altran and General Electric announced they have signed a Memorandum of Understanding to form an alliance focused on delivering the next generation of Industrial Internet solutions that support secure connected assets and objects; industrial analytics and data science; and machine data management. This partnership complements both GE’s & Altran’s deep industrial and software expertise in order to power economic growth in France and globally. Altran and GE continue to build out their Industrial Internet ecosystem of global alliances and partnerships with this latest MOU. The companies are negotiating to define the scope of services each will provide under the terms of the agreement. The alliance is expected to begin operations in the fourth quarter of 2015. This agreement has been signed this day at the International Paris Air Show.
05:31 EDTPFEPfizer initiated with an Overweight at Piper Jaffray
Target $45.
June 16, 2015
19:47 EDTMSFTXbox chief says digital game sales 'really strong,' WSJ reports
Subscribe for More Information
16:01 EDTGEApple Twitter Facebook Bank of America Yahoo Netflix Alibaba WisdomTree Coca-Cola Goldman Sachs Micron General Electric
iPath S&P 500 VIX Short-Term Futures down 33c to 18.68. Option volume leaders: AAPL TWTR FB BAC YHOO NFLX BABA WETF KO GS MU GE.
15:38 EDTBBRYLenovo executive comments on potential BlackBerry acquisition, BNN says
Subscribe for More Information
14:23 EDTTEVAReceptos price target raised to $348 at Wedbush on M&A potential
Wedbush analysts Liana Moussatos and Kelechi Chikere said they'd interpreted Receptos (RCPT) comments with its earnings report in May about its ability to commercialize ozanimod on its own as a message to potential buyers that their bids were too low. Following a recent report from Proactive Investors, which claimed that Receptos had turned down bids of $200 per share from AstraZeneca (AZN) and $280 per share from Teva (TEVA) and Gilead (GILD), the analysts said they have reconsidered their valuation assumptions, as they believe these bid values could be accurate. Wedbush raised its fair value estimate on Receptos to $348 from $211, citing a belief in increased industry interest in ozanimod and the rest of Receptos’ pipeline, and maintains an Outperform rating on the stock.
14:12 EDTTEVAAbbott backing marginally ups chances of Mylan-Perrigo deal, says BMO Capital
Subscribe for More Information
12:04 EDTMSFTBox enhances integration with Microsoft Office Online
Box (BOX) announced a deep integration with Microsoft (MSFT) Office Online that will transform collaboration for joint customers. The company added, "Today’s update extends the reach of Box’s powerful integrations with Office 365 for the desktop, Office on iOS and Outlook, and demonstrates Box’s commitment to the Office 365 Cloud Storage Partner Program." “Box and Microsoft are working together to help businesses and individuals be more productive, collaborative and successful,” said Kirk Koenigsbauer, corporate vice president for Office at Microsoft. “We're thrilled about this latest offering to give our joint customers more choice and simplicity for how they work together with documents and digital content.” The Box integration with Office Online will enable users to easily browse, open and edit Office Online files directly from Box, as well as automatically save all changes made in Office Online back to Box in real-time. Together, these enhancements eliminate the need to upload or download files or move back-and-forth between applications, simplifying workflows and mitigating the security risks that come with locally stored content.
11:06 EDTTEVATeva says 'fully committed' to bid for Mylan, Bloomberg reports
After Abbott (ABT) announced earlier that it intends to vote its 14.5% stake in Mylan (MYL) in favor of Mylan's proposed acquisition of Perrigo (PRGO), a Teva (TEVA) spokesperson told Bloomberg in an email that the company remains "fully committed" to is offer to acquire Mylan, which Teva said is better than Mylan's suggested deal for Perrigo.
10:58 EDTLVSCasino stocks strengthen after report of investor Kerkorian death
10:29 EDTTEVAGeneric drugs may be targets of congressional price probe, Bloomberg says
In addition to branded drugs that were cited for "staggering" price increases in a congressional probe on drug prices being led by U.S. Senator Bernie Saunders, generic drug makers may also be targeted, stated Bloomberg Intelligence. Data show some generics, including clomipramine hydrochloride and tetracycline, have seen "aggressive" quarterly price increases, the report noted. Generic drug makers that could be caught up in the probe include Mallinckrodt (MNK), Teva (TEVA), Novartis' (NVS) Sandoz unit, Mylan (MYL), Taro Pharmaceutical (TARO) and Teva (TEVA). Mallinckrodt shares are down about 4% in early trading.
09:46 EDTMSFTMicrosoft to encrypt all search traffic by default
Microsoft's Bing has announced that it will encrypt its search traffic by default. Bing has already been offering users the option to encrypt search traffic for about a year and a half now. Beginning this summer, Bing will begin the process of encrypting search traffic by default. With the move to encrypted search by default Bing will continue to pass along a referrer string so that marketers and webmasters will be able to identify traffic as coming from Bing. However, to further protect users’ privacy, Bing will not include the used query terms. Reference Link
09:36 EDTBBRY, LVSActive equity options trading on open
Subscribe for More Information
08:09 EDTGEGE's renewable energy business announces $25M investment from TerraForm
Subscribe for More Information
08:08 EDTLVSMacau Q2 estimates lowered below consensus at Morgan Stanley
Following a trip to Macau, Morgan Stanley said the market is still far from a turnaround and trends are still weakening. The firm does not expect Q2 to-date GGR results of (36%) to improve, below its prior estimate of (30%), and lowered forecasts. Morgan Stanley's Q2 Macau property-level EBITDA estimate for MGM Resorts (MGM) falls to $121M vs. consensus of $141M, Wynn Resorts (WYNN) lowered to $200M vs. consensus of $210M, and Las Vegas Sands (LVS) drops to $521M vs. consensus of $549M.
08:05 EDTTEVATeva reports ARM-TD study meets primary endpoint
Teva Pharmaceutical (TEVA) announced positive top-line results from the pivotal clinical study Aim to Reduce Movements in Tardive Dyskinesia, or ARM-TD, designed to evaluate the efficacy of SD-809 in the treatment of moderate to severe tardive dyskinesia. Top-line data showed that the study met its primary endpoint and demonstrated a positive trend in all secondary endpoints. The primary endpoint of ARM-TD was the change in the Abnormal Involuntary Movement Scale, or AIMS, from baseline to end of therapy, assessed by blinded centralized video rating. The study results show patients taking SD-809 achieved an improvement of 3.0 points on the AIMS score from baseline to end of therapy compared to 1.6 points in placebo for a clinically meaningful effect. Study results also demonstrated a favorable safety and tolerability profile of SD-809. Fewer patients taking SD-809 than placebo experienced serious adverse events. Three patients discontinued from the study for adverse events. For all other side effects reported in the study, rates in the SD-809 group were similar or lower than the placebo group. Further analysis of the additional data from the study is ongoing and details will be shared at future medical meetings and through peer-reviewed publication, the company said. SD-809 became part of Teva’s central nervous system product portfolio with the acquisition of Auspex Pharmaceuticals in May.
07:31 EDTTEVAEagle Pharmaceuticals price target raised to $95 from $65 at Cantor
Subscribe for More Information
06:27 EDTMSFTMicrosoft opens branded store on Indian e-commerce platform Snapdeal
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use